AAC (Ares Acquisition Corporation III)
Insider Trading Activity
Every open-market purchase and sale reported by AAC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2019-06-21 | MICHAEL NANKO | President and COO | D | — | — |
| 2019-06-12 | LUCIUS E BURCH III | Director | Buy | — | — |
| 2019-06-12 | LUCIUS E BURCH III | Director | Buy | — | — |
| 2019-06-11 | STEPHEN EBBETT | See remarks | Buy | — | — |
| 2019-06-06 | DAVID C KLOEPPEL | Director | D | — | — |
| 2019-05-22 | W LARRY CASH | Director | Buy | — | — |
| 2019-04-26 | MICHAEL J. BLACKBURN | Director | A | — | — |
| 2019-04-26 | LUCIUS E BURCH III | Director | A | — | — |
| 2019-04-26 | David W. Hillis SR. | Director | A | — | — |
| 2019-04-26 | Darrell S. Freeman | Director | A | — | — |
| 2019-04-26 | W LARRY CASH | Director | A | — | — |
| 2019-04-26 | DAVID C KLOEPPEL | Director | A | — | — |
| 2019-04-26 | Jerry D. Bostelman | Director | A | — | — |
| 2018-12-03 | MICHAEL NANKO | President and COO | Buy | — | — |
| 2018-11-30 | W LARRY CASH | Director | Buy | — | — |
| 2018-11-30 | Darrell S. Freeman | Director | Buy | — | — |
| 2018-09-28 | STEPHEN EBBETT | See remarks | A | — | — |
| 2018-05-24 | Michael T. Cartwright | Chairman and CEO | Sell | — | — |
| 2018-05-08 | W LARRY CASH | Director | Buy | — | — |
| 2018-04-06 | MICHAEL NANKO | President and COO | A | — | — |
| 2018-04-06 | Thomas W. Doub | Chief Clinical Officer and CCO | A | — | — |
| 2018-04-06 | Jerry D. Bostelman | Director | A | — | — |
| 2018-04-06 | LUCIUS E BURCH III | Director | A | — | — |
| 2018-04-06 | Andrew W. McWilliams | Chief Financial Officer | A | — | — |
| 2018-04-06 | DAVID C KLOEPPEL | Director | A | — | — |
| 2018-04-06 | Michael T. Cartwright | Chairman and CEO | A | — | — |
| 2018-04-06 | Darrell S. Freeman | Director | A | — | — |
| 2018-04-06 | RICHARD E RAGSDALE | Director | A | — | — |
| 2018-04-03 | DAVID C KLOEPPEL | Director | Sell | — | — |
| 2018-03-15 | Michael T. Cartwright | Chairman and CEO | Sell | — | — |
| 2018-03-15 | DAVID C KLOEPPEL | Director | Sell | — | — |
| 2018-03-08 | MICHAEL J. BLACKBURN | Director | MIXED | — | — |
| 2018-03-07 | W LARRY CASH | Director | Buy | — | — |
| 2018-02-28 | DAVID C KLOEPPEL | Director | Sell | — | — |
| 2018-01-30 | DAVID C KLOEPPEL | Director | Sell | — | — |
| 2018-01-03 | Kathryn Sevier Phillips | Chief Legal Officer, GC & Sec. | F | — | — |
| 2018-01-03 | Michael T. Cartwright | Chairman and CEO | F | — | — |
| 2018-01-03 | Kirk R. Manz | — | F | — | — |
| 2018-01-03 | Andrew W. McWilliams | Chief Financial Officer | F | — | — |
| 2018-01-03 | Thomas W. Doub | Chief Clinical Officer and CCO | F | — | — |
| 2017-11-30 | W LARRY CASH | Director | Buy | — | — |
| 2017-11-15 | W LARRY CASH | Director | Buy | — | — |
| 2017-11-15 | Michael T. Cartwright | Chairman and CEO | Sell | — | — |
| 2017-11-08 | Jerrod N. Menz | 10%+ Owner | Sell | — | — |
| 2017-10-10 | Andrew W. McWilliams | Chief Accounting Officer | F | — | — |
| 2017-10-03 | Kathryn Sevier Phillips | Chief Legal Officer, GC & Sec. | F | — | — |
| 2017-10-03 | Andrew W. McWilliams | Chief Accounting Officer | F | — | — |
| 2017-10-03 | Kirk R. Manz | Chief Financial Officer | F | — | — |
| 2017-10-03 | Michael T. Cartwright | Chairman and CEO | F | — | — |
| 2017-07-05 | Andrew W. McWilliams | Chief Accounting Officer | F | — | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AAC quote page; the site-wide leaderboard is on the insider transactions hub.